Aclarion Earnings Call Transcripts
Fiscal Year 2025
-
Strong financial footing and NASDAQ compliance support rapid growth in a $10B+ market, driven by a patented, AI-powered SaaS diagnostic for chronic back pain. Clinical trials and payer adoption in London and the U.S. are accelerating physician uptake and scan volumes.
-
A novel, non-invasive diagnostic for chronic low back pain is targeting a $600M+ U.S. market, supported by strong clinical evidence, a robust patent portfolio, and a seasoned management team. Key catalysts include the CLARITY trial, payer adoption in the U.K., and U.S. reimbursement progress.
Fiscal Year 2024
-
MR spectroscopy technology enables non-invasive, cost-saving diagnosis of painful lumbar discs, with strong clinical validation and growing payer coverage. Expansion is underway in both the U.S. and U.K., supported by a robust patent portfolio and experienced leadership.
-
AI-driven, non-invasive diagnostics for spinal pain are gaining traction, with strong clinical evidence, successful payer coverage in the UK, and ongoing expansion efforts in the US. Key milestones include increasing MRI activations, scan volumes, and launching the CLARITY trial in Q4 2024.